Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Tesamorelin binds the at the pituitary, restoring pulsatile growth hormone secretion and downstream IGF-1 signalling. The lipid-modification on the increases plasma versus native GHRH(1–44).
02
Research applications
- Endocrine pathway and - pharmacology research
- HIV-associated lipodystrophy clinical research
- Hepatic steatosis and NAFLD trial research in people with HIV
- Comparative research
Evidence at a glance
What's behind this profile
3 citations · 2011–2024
- Human
- 2
- Review
- 1
Studies in human volunteers or patients (incl. early-phase trials).
Narrative or systematic reviews; no primary data.
Publication years
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 2 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Tesamorelin (drug approval review)
2011
Grunfeld C et al. · Nature Reviews Drug Discovery
- Model
- Drug approval review
- Sample
- N/A (review)
Reviewed the regulatory and clinical evidence supporting FDA approval of tesamorelin for reducing excess abdominal fat in patients with HIV-associated lipodystrophy.
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
2020
Fourman LT et al. · JCI Insight
- Model
- Randomised placebo-controlled trial with paired liver biopsies (people with HIV and NAFLD)
- Sample
- Paired specimens from the parent clinical trial cohort
Tesamorelin was associated with increased hepatic oxidative phosphorylation and decreased inflammatory and fibrosis-related signatures in paired liver biopsies.
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
2024
Russo SC et al. · AIDS
- Model
- Randomised double-blind trial in people with HIV on integrase-inhibitor regimens
- Sample
- n=38 randomised; 31 completed 12-month study
Tesamorelin reduced visceral and hepatic fat and trunk-to-appendicular fat ratio versus placebo without significantly worsening glycaemic control over 12 months.
Evidence caveats
- FDA approval is specific to HIV-associated lipodystrophy. Use outside that indication is investigational and is not endorsed here.
- Clinical decisions involving tesamorelin must be made with a qualified healthcare professional. Palthera does not provide dosage or administration guidance.
04
Storage and handling
Approved product follows manufacturer cold-chain instructions. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Approved-product handling follows the manufacturer label; research-grade material is separate and must be documented per protocol.
- Maintain cold-chain records per supplier guidance.
- Record conditions and dates for each batch.